The start of the clinical validation study represents an important step in the development of KidneyIntelX™, the company’s AI-enabled diagnostic for fast-progressing chronic kidney disease (CKD). KidneyIntelX™, which is being developed in close collaboration with Mount Sinai Health System (a leading US healthcare group), addresses a substantial unmet need: CKD affects approximately 30m people in the US alone, most commonly as a result of diabetes and/or hypertension. Often asymptomatic until 70- ....
23 Jan 2019
Start of clinical validation study for KidneyIntelX™
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Start of clinical validation study for KidneyIntelX™
Renalytix Plc (RENX:LON) | 26.5 -0.3 (-3.6%) | Mkt Cap: 33.4m
- Published:
23 Jan 2019 -
Author:
Jens Lindqvist -
Pages:
3
The start of the clinical validation study represents an important step in the development of KidneyIntelX™, the company’s AI-enabled diagnostic for fast-progressing chronic kidney disease (CKD). KidneyIntelX™, which is being developed in close collaboration with Mount Sinai Health System (a leading US healthcare group), addresses a substantial unmet need: CKD affects approximately 30m people in the US alone, most commonly as a result of diabetes and/or hypertension. Often asymptomatic until 70- ....